These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 17071605)
1. A novel role of myosin VI in human prostate cancer. Dunn TA; Chen S; Faith DA; Hicks JL; Platz EA; Chen Y; Ewing CM; Sauvageot J; Isaacs WB; De Marzo AM; Luo J Am J Pathol; 2006 Nov; 169(5):1843-54. PubMed ID: 17071605 [TBL] [Abstract][Full Text] [Related]
2. Myosin VI is a modulator of androgen-dependent gene expression. Loikkanen I; Toljamo K; Hirvikoski P; Väisänen T; Paavonen TK; Vaarala MH Oncol Rep; 2009 Nov; 22(5):991-5. PubMed ID: 19787211 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Puri C; Chibalina MV; Arden SD; Kruppa AJ; Kendrick-Jones J; Buss F Oncogene; 2010 Jan; 29(2):188-200. PubMed ID: 19855435 [TBL] [Abstract][Full Text] [Related]
4. Migrating with myosin VI. Knudsen B Am J Pathol; 2006 Nov; 169(5):1523-6. PubMed ID: 17071577 [No Abstract] [Full Text] [Related]
5. The microRNA profile of prostate carcinoma obtained by deep sequencing. Szczyrba J; Löprich E; Wach S; Jung V; Unteregger G; Barth S; Grobholz R; Wieland W; Stöhr R; Hartmann A; Wullich B; Grässer F Mol Cancer Res; 2010 Apr; 8(4):529-38. PubMed ID: 20353999 [TBL] [Abstract][Full Text] [Related]
6. [Myosin VI: the unique motor protein of the actin cytoskeleton]. Lenartowska M; Walczewski J Postepy Biochem; 2011; 57(1):63-73. PubMed ID: 21735821 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of myosin VI by lentivirus-mediated short hairpin RNA suppresses proliferation of melanoma. Li H; Zhou F; Wang H; Lin D; Chen G; Zuo X; Sun L; Zhang X; Yang S Mol Med Rep; 2015 Nov; 12(5):6801-6. PubMed ID: 26324058 [TBL] [Abstract][Full Text] [Related]
8. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417 [TBL] [Abstract][Full Text] [Related]
9. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705 [TBL] [Abstract][Full Text] [Related]
10. Myosin VI is a processive motor with a large step size. Rock RS; Rice SE; Wells AL; Purcell TJ; Spudich JA; Sweeney HL Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13655-9. PubMed ID: 11707568 [TBL] [Abstract][Full Text] [Related]
11. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Nadiminty N; Dutt S; Tepper C; Gao AC Prostate; 2010 Feb; 70(3):276-87. PubMed ID: 19827050 [TBL] [Abstract][Full Text] [Related]
12. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022 [TBL] [Abstract][Full Text] [Related]
13. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492 [TBL] [Abstract][Full Text] [Related]
14. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453 [TBL] [Abstract][Full Text] [Related]
16. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells. Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065 [TBL] [Abstract][Full Text] [Related]
17. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. Bouras T; Frauman AG J Pathol; 1999 Aug; 188(4):382-8. PubMed ID: 10440748 [TBL] [Abstract][Full Text] [Related]
18. MYH6 suppresses tumor progression by downregulating KIT expression in human prostate cancer. Wang F; Shen H; Li K; Ding Y; Wang J; Sun J Sci Rep; 2024 Aug; 14(1):19685. PubMed ID: 39181964 [TBL] [Abstract][Full Text] [Related]
19. The significance of LMO2 expression in the progression of prostate cancer. Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Steele VE; Arnold JT; Lei H; Izmirlian G; Blackman MR Anticancer Res; 2006; 26(5A):3205-15. PubMed ID: 17094431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]